D-Cycloserine Antagonist Reduces Psychiatric Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression and schizophrenia are limited by severe side effects such as anxiety, akathisia, and suicidality, with no approved treatments for antipsychotic-induced akathisia and anxiety, and existing antidepressants increasing the risk of suicidal tendencies.
Innovation Solution
Formulations combining antipsychotic and/or antidepressant medications with selective 5-HT2A receptor antagonists and competitive NMDAR antagonists, specifically using D-cycloserine at doses producing sustained blood levels above 25 micrograms/mL to reduce anxiogenic side effects and enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotic and antidepressant medications are used to treat depression and schizophrenia, then treatment efficacy is improved, but anxiogenic side effects such as anxiety, akathisia, and suicidality increase
Solution Approach 1:
The patent introduces D-cycloserine as an intermediary substance that mediates between the antidepressant/antipsychotic medications and the patient's nervous system. D-cycloserine acts as a competitive NMDAR antagonist, blocking excessive glutamate activity that contributes to anxiogenic side effects, while allowing the primary medications to maintain their therapeutic effects on depression and psychosis.
Solution Approach 2:
The patent extracts and isolates the harmful anxiogenic effects from the beneficial therapeutic effects of antidepressant and antipsychotic medications. By specifically targeting and blocking NMDAR-mediated anxiety pathways with D-cycloserine, the treatment separates the unwanted side effects from the desired clinical outcomes, allowing continued use of effective psychiatric medications without the full burden of their side effect profile.
2Object-generated harmful factors
If D-cycloserine is added to the treatment regimen to reduce side effects, then anxiogenic symptoms are reduced, but treatment complexity increases
Solution Approach 1:
D-cycloserine serves multiple functions simultaneously: it acts as a competitive NMDAR antagonist to reduce anxiety and akathisia, enhances the efficacy of antidepressant medications, and allows for the continuation of antipsychotic treatment. This multi-functionality reduces the need for separate interventions for different side effects, simplifying the overall treatment approach despite adding one medication.
3Reliability
If higher doses of antidepressants are used to improve symptom management, then depression symptoms are better controlled, but the risk of suicidal tendencies and anxiogenic effects increases
Solution Approach 1:
The patent applies preliminary anti-action by administering D-cycloserine to preemptively block the development of anxiogenic side effects and suicidal risk before they can occur. By pre-blocking NMDAR-mediated pathways that lead to anxiety and suicidality, the treatment prevents these harmful effects from emerging, even when higher doses of antidepressants are used to achieve optimal symptom control.
Data Source
AI summary
This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.